EMA Authorised: Nuvaxovid (SARS CoV-2 (Original) recombinant spike protein;SARS-CoV-2 (Omicron XBB.1.5) recombinant spike protein) — Sanofi Winthrop Industrie

View source ↗

Summary

EMA has authorised Nuvaxovid (SARS-CoV-2 original and Omicron XBB.1.5 recombinant spike proteins) for COVID-19 virus infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Virus Infection

Drugs mentioned

• Nuvaxovid (NVX-CoV2373)

Snippet

Status: Authorised. Therapeutic area: COVID-19 virus infection. MAH: Sanofi Winthrop Industrie. Decision date: 28/07/2026